Trial Profile
Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Acronyms PLUMMB
- 16 Apr 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2024.
- 16 Apr 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Apr 2022.
- 16 Apr 2021 Status changed from active, no longer recruiting to recruiting.